Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase three clinical trial of the combination of HLX78 (lasofoxifene) and abemaciclib to the combination of fulvestrant and abemaciclib in mainland China, excluding the Hong Kong, Macau, and Taiwan regions.
The combination is being tested for the treatment of pre- and post-menopausal women and men with locally advanced or metastatic breast cancer, a Tuesday bourse filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.